Clin Pediatr Hematol Oncol.  2015 Oct;22(2):186-189. 10.15264/cpho.2015.22.2.186.

A Case of Long-term Survival with Autologous Recovery after Double Cord Blood Transplantation for Juvenile Myelomonocytic Leukemia

Affiliations
  • 1Department of Pediatrics, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea. kanghj@snu.ac.kr

Abstract

A 1.1 year old boy was admitted to the Seoul National University Children's Hospital because of incidental findings of hepatosplenomegaly, skin lesion and multiple intra- abdominal lymphadenopathies. Anemia and thrombocytopenia were found based on the initial complete blood count (CBC) measurements. Because of bicytopenia and hepatosplenomegaly, bone marrow examination was performed which revealed hypercellular marrow with increased monocytes and granulopoiesis. The hemoglobin F level was high for his age, and monocyte production was increased. The patient was diagnosed with juvenile myelomonocytic leukemia at the age of 1.2 years. Chemotherapy with cytarabine, etoposide, vincristine, and isotretinoin was initiated. After 6 cycles of chemotherapy, the CBC normalized. He underwent double cord blood transplantation (dCBT), but chimerism studies showed autologous recovery. However, he did not show relapse during the 5 years post-transplant during which he received isotretinoin. He is surviving disease-free 9 years after dCBT.

Keyword

Juvenile myelomonocytic leukemia; Doule cord blood transplantation; Autologous recovery; Outcome

MeSH Terms

Anemia
Blood Cell Count
Bone Marrow
Bone Marrow Examination
Chimerism
Cytarabine
Drug Therapy
Etoposide
Fetal Blood*
Fetal Hemoglobin
Humans
Incidental Findings
Isotretinoin
Leukemia, Myelomonocytic, Juvenile*
Male
Monocytes
Recurrence
Seoul
Skin
Thrombocytopenia
Vincristine
Cytarabine
Etoposide
Fetal Hemoglobin
Isotretinoin
Vincristine
Full Text Links
  • CPHO
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr